Advanced SearchSearch Tips
Effect of Recombinant CagL Immunization on the Gastric Diseases Induced by Helicobacter pylori in Mongolian gerbils
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
  • Journal title : The Korean Journal of Microbiology
  • Volume 48, Issue 2,  2012, pp.109-115
  • Publisher : The Microbiological Society of Korea
  • DOI : 10.7845/kjm.2012.48.2.109
 Title & Authors
Effect of Recombinant CagL Immunization on the Gastric Diseases Induced by Helicobacter pylori in Mongolian gerbils
Bak, Eun-Jung; Jang, Sung-Il; Choi, Yun-Hui; Kim, Jin-Moon; Kim, Ae-Ryun; Kim, Ji-Hye; Woo, Gye-Hyeong; Yoo, Yun-Jung; Lee, Sung-Haeng; Cha, Jeong-Heon;
  PDF(new window)
Helicobacter pylori is an important factor of chronic gastritis, digestive ulcer, and stomach cancer. CagL, a virulence factor of H. pylori, is well-known as a pilus protein which acts as adhesion to host cell and a component of Type 4 secretion system. In this study, we evaluated the protective response of recombinant CagL protein (rCagL) using Mongolian gerbil animal model for H. pylori infection. The cagL gene was cloned from 26695 H. pylori followed by over-expression and purification of the protein in E. coli. Mongolian gerbils were immunized with rCagL protein mixed with aluminum adjuvant via intramuscular injections once a week during 4 weeks. At a week after the last immunization, the Mongolian gerbils were administrated with H. pylori 7.13 strain into the stomach and sacrificed to measure antibody titer on rCagL by ELISA and bacterial colonization in the stomach, and to examine the histopathological changes and cytokine expression at 6 week after challenge. Antibody titers on recombinant protein were significantly increased from a week after the first immunization. There was no significant change of the number of bacterial colony between control group and immunized group. The relative stomach weight was significantly decreased in immunized group, but the significant change of histopathological assessment was not observed in the stomach. Cytokine expression such as IL- and KC also was not significantly different between control and immunized groups. These results indicate that rCagL could effectively induce the formation of the specific IgG antibodies. However, bacterial colonization and histopathological lesions could not be inhibited by the immunization in the stomach, indicating not enough protection against H. pylori infection. We consider that along with CagL other adequate antigens could be needed stimulating immune response and inducing protective effects against gastric disease, and also a better adjuvant could be considered.
Helicobacter pylori;CagL;IgG antibodies;immunization;Mongolian gerbils;
 Cited by
Amieva, M.R., Vogelmann, R., Covacci, A., Tompkins, L.S., Nelson, W.J., and Falkow, S. 2003. Disruption of the epithelial apical-junctional complex by Helicobacter pylori CagA. Science 300, 1430-1434. crossref(new window)

Backert, S. and Meyer, T.F. 2006. Type IV secretion systems and their effectors in bacterial pathogenesis. Curr. Opin. Microbiol. 9, 207-217. crossref(new window)

Cao, X., Tsukamoto, T., Seki, T., Tanaka, H., Morimura, S., Cao, L., Mizoshita, T., Ban, H., Toyoda, T., Maeda, H., and et al. 2008. 4-Vinyl-2,6-dimethoxyphenol (canolol) suppresses oxidative stress and gastric carcinogenesis in Helicobacter pylori-infected carcinogen-treated Mongolian gerbils. Int. J. Cancer 122, 1445-1454.

Cascales, E. and Christie, P.J. 2003. The versatile bacterial type IV secretion systems. Nat. Rev. Microbiol. 1, 137-149. crossref(new window)

Covacci, A. and Rappuoli, R. 2000. Tyrosine-phosphorylated bacterial proteins: Trojan horses for the host cell. J. Exp. Med. 191, 587-592. crossref(new window)

Crabtree, J.E., Court, M., Aboshkiwa, M.A., Jeremy, A.H., Dixon, M.F., and Robinson, P.A. 2004. Gastric mucosal cytokine and epithelial cell responses to Helicobacter pylori infection in Mongolian gerbils. J. Pathol. 202, 197-207. crossref(new window)

Del Giudice, G., Covacci, A., Telford, J.L., Montecucco, C., and Rappuoli, R. 2001. The design of vaccines against Helicobacter pylori and their development. Annu. Rev. Immunol. 19, 523-563. crossref(new window)

Durrani, Z. and Rijpkema, S. 2003. Orogastric vaccination of guinea pigs with Helicobacter pylori sonicate and a high dose of cholera toxin lowers the burden of infection. FEMS Immunol. Med. Microbiol. 36, 169-173. crossref(new window)

Gottwein, J.M., Blanchard, T.G., Targoni, O.S., Eisenberg, J.C., Zagorski, B.M., Redline, R.W., Nedrud, J.G., Tary-Lehmann, M., Lehmann, P.V., and Czinn, S.J. 2001. Protective anti-Helicobacter immunity is induced with aluminum hydroxide or complete Freund's adjuvant by systemic immunization. J. Infect. Dis. 184, 308-314. crossref(new window)

Graham, D.Y. 1998. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology 115, 1272-1277. crossref(new window)

Israel, D.A., Salama, N., Arnold, C.N., Moss, S.F., Ando, T., Wirth, H.P., Tham, K.T., Camorlinga, M., Blaser, M.J., Falkow, S., and et al. 2001. Helicobacter pylori strain-specific differences in genetic content, identified by microarray, influence host inflammatory responses. J. Clin. Invest. 107, 611-620. crossref(new window)

Jeremy, A.H., Du, Y., Dixon, M.F., Robinson, P.A., and Crabtree, J.E. 2006. Protection against Helicobacter pylori infection in the Mongolian gerbil after prophylactic vaccination. Microbes Infect. 8, 340-346. crossref(new window)

Kwok, T., Zabler, D., Urman, S., Rohde, M., Hartig, R., Wessler, S., Misselwitz, R., Berger, J., Sewald, N., Konig, W., and et al. 2007. Helicobacter exploits integrin for type IV secretion and kinase activation. Nature 449, 862-866. crossref(new window)

Lee, C.K. 2001. Vaccination against Helicobacter pylori in non-human primate models and humans. Scand. J. Immunol. 53, 437-442. crossref(new window)

Lee, C.K., Soike, K., Giannasca, P., Hill, J., Weltzin, R., Kleanthous, H., Blanchard, J., and Monath, T.P. 1999. Immunization of rhesus monkeys with a mucosal prime, parenteral boost strategy protects against infection with Helicobacter pylori. Vaccine 17, 3072-3082. crossref(new window)

Maeda, K., Yamashiro, T., Minoura, T., Fujioka, T., Nasu, M., and Nishizono, A. 2002. Evaluation of therapeutic efficacy of adjuvant Helicobacter pylori whole cell sonicate in mice with chronic H. pylori infection. Microbiol. Immunol. 46, 613-620. crossref(new window)

Marchetti, M., Rossi, M., Giannelli, V., Giuliani, M.M., Pizza, M., Censini, S., Covacci, A., Massari, P., Pagliaccia, C., Manetti, R., and et al. 1998. Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant. Vaccine 16, 33-37. crossref(new window)

Marshall, B.J. and Warren, J.R. 1984. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1, 1311-1315.

Nystrom, J., Raghavan, S., and Svennerholm, A.M. 2006. Mucosal immune responses are related to reduction of bacterial colonization in the stomach after therapeutic Helicobacter pylori immunization in mice. Microbes Infect. 8, 442-449. crossref(new window)

Parsonnet, J., Friedman, G.D., Vandersteen, D.P., Chang, Y., Vogelman, J.H., Orentreich, N., and Sibley, R.K. 1991. Helicobacter pylori infection and the risk of gastric carcinoma. N. Engl. J. Med. 325, 1127-1131. crossref(new window)

Rossi, G., Ruggiero, P., Peppoloni, S., Pancotto, L., Fortuna, D., Lauretti, L., Volpini, G., Mancianti, S., Corazza, M., Taccini, E., and et al. 2004. Therapeutic vaccination against Helicobacter pylori in the beagle dog experimental model: safety, immunogenicity, and efficacy. Infect. Immun. 72, 3252-3259. crossref(new window)

Ruggiero, P., Peppoloni, S., Rappuoli, R., and Del Giudice, G. 2003. The quest for a vaccine against Helicobacter pylori: how to move from mouse to man? Microbes Infect. 5, 749-756. crossref(new window)

Sakagami, T., Dixon, M., O'Rourke, J., Howlett, R., Alderuccio, F., Vella, J., Shimoyama, T., and Lee, A. 1996. Atrophic gastric changes in both Helicobacter felis and Helicobacter pylori infected mice are host dependent and separate from antral gastritis. Gut 39, 639-648. crossref(new window)

Segal, E.D., Cha, J., Lo, J., Falkow, S., and Tompkins, L.S. 1999. Altered states: involvement of phosphorylated CagA in the induction of host cellular growth changes by Helicobacter pylori. Proc. Natl. Acad. Sci. USA 96, 14559-14564. crossref(new window)

Shaffer, C.L., Gaddy, J.A., Loh, J.T., Johnson, E.M., Hill, S., Hennig, E.E., McClain, M.S., McDonald, W.H., and Cover, T.L. 2011. Helicobacter pylori exploits a unique repertoire of type IV secretion system components for pilus assembly at the bacteria-host cell interface. PLoS Pathog. 7, e1002237. crossref(new window)

Sougioultzis, S., Lee, C.K., Alsahli, M., Banerjee, S., Cadoz, M., Schrader, R., Guy, B., Bedford, P., Monath, T.P., Kelly, C.P., and et al. 2002. Safety and efficacy of E. coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori. Vaccine 21, 194-201. crossref(new window)

Ta, L.H., Hansen, L.M., Sause, W.E., Shiva, O., Millstein, A., Ottemann, K.M., Castillo, A.R., and Solnick, J.V. 2012. Conserved transcriptional unit organization of the cag pathogenicity island among Helicobacter pylori strains. Front. Cell. Infect. Microbiol. 2, 1-14.

Tegtmeyer, N., Hartig, R., Delahay, R.M., Rohde, M., Brandt, S., Conradi, J., Takahashi, S., Smolka, A.J., Sewald, N., and Backert, S. 2010. A small fibronectin-mimicking protein from bacteria induces cell spreading and focal adhesion formation. J. Biol. Chem. 285, 23515-23526. crossref(new window)

Wang, J., Court, M., Jeremy, A.H., Aboshkiwa, M.A., Robinson, P.A., and Crabtree, J.E. 2003. Infection of Mongolian gerbils with Chinese Helicobacter pylori strains. FEMS Immunol. Med. Microbiol. 36, 207-213. crossref(new window)

Wu, C., Shi, Y., Guo, H., Zou, W.Y., Guo, G., Xie, Q.H., Mao, X.H., Tong, W.D., and Zou, Q.M. 2008. Protection against Helicobacter pylori infection in mongolian gerbil by intragastric or intramuscular administration of H. pylori multicomponent vaccine. Helicobacter 13, 191-199. crossref(new window)